Administration of Nutritional Supplements Acts as Prevalent Trend in Urinary Tract Infection Treatment Market
According to our new market research study on “Urinary Tract Infection Treatment Marketto 2027 – COVID-19 Impact and Global Analysis– by Drug Class, Indication, and Distribution Channel,” the market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent.
The urinary tract infection treatment market, by indication, is segmented into complicated urinary tract infections and uncomplicated urinary tract infections. The complicated urinary tract infections segment held a larger share of the market in 2019, and it is also anticipated to register a higher CAGR in the market during the forecast period.
Nutritional supplements, such as cranberry juice, have been proven to be clinically effective against UTIs. Cranberries are the most excellent food for preventing UTIs as they contain an anti-adhesive substance that inhibit adherence of bacteria to the walls of the urethra, thereby naturally preventing bacterial infection. Additionally, mannose is a natural sugar found in several fruits and vegetables, and it can prevent urinary infections and cystitis in women.
In July 2020, the US FDA, in a letter of enforcement prudence, announced that it does not intend to object the use of specific qualified health claims regarding consuming certain cranberry products and a reduced risk of recurrent UTIs in healthy women. Moreover, the FDA stated that consuming 500 mg [X capsules/tablets/soft gels] each day may help reduce the risk of recurrent UTI in healthy women. Additionally, in 2004, France became the first country to approve a health claim for the North American cranberry (Vacciniummacrocarpon) as 36 mg of proanthocyanidins has been state to help reduce the adhesion of certain E. coli to urinary tract walls.
The American University of Beirut Medical Center is assessing Vitamin C pills to prevent catheter-associated UTIs in women undergoing elective gynecological surgeries. Further, AmPurity Nutraceuticals, LLC, in collaboration with Arkansas Urology, is assessing the supplement—WelTract—a commercially available dietary supplement capsules containing extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D for the treatment of recurrent UTI.
The COVID-19 pandemic was first reported in December 2019 in Wuhan (China). The impacts of this outbreak are being felt across several markets in the world. The demand for urinary tract infection treatment solutions has reduced amid this global crisis due to a significant shift in the focus toward the management, treatment, and prevention of COVID-19.
Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market.
The report segments global urinary tract infection treatment market as follows:
By Drug Class
- Penicillin and Combinations
- Aminoglycoside Antibiotics
- Nutritional Supplements
- Complicated Urinary Tract Infection
- Uncomplicated Urinary Tract Infection
By Distribution Channel
- Hospital Pharmacies
- Gynaecology and Urology Clinics
- Retail Pharmacies and Drug Store
- Online Drug Stores
- North America
- Asia Pacific (APAC)
- South Korea
- Middle East and Africa (MEA)
- Saudi Arabia
- South Africa
- South and Central America (SCAM)